Our Take
Early-stage data against a narrow disease category doesn't yet establish superiority over an approved competitor; wait for phase 3 results before treating this as a competitive claim.
Why it matters
Vascular anomalies affect thousands of patients with limited options, and any new effective therapy reshapes treatment algorithms. Vijoice's recent approval left room for alternatives that might work better or faster.
Do this week
Clinicians: monitor Relay's phase 3 timeline and request access to the trial protocol or published results when available, so you can assess zovegalisib against your current patient management approach.
Early trial results for zovegalisib
Relay Therapeutics announced early findings from its trial of zovegalisib in patients with vascular anomalies, a group of rare chronic vascular conditions. The data suggest the drug could outperform Novartis' recently approved Vijoice in this indication (per BioPharma Dive reporting). Vascular anomalies currently have few available treatments, making any new option potentially significant for affected patients.
The announcement follows Vijoice's recent regulatory approval, which was itself the first targeted therapy for this disease category. Relay's early results position zovegalisib as a potential alternative in a therapeutic space with minimal competition.
A narrow field, a tight race
Vascular anomalies are rare and chronic, affecting a small but underserved patient population. Until Vijoice's approval, standard care was limited to surgical intervention and supportive measures. Vijoice's arrival opened the market; early promise from zovegalisib suggests that market will fragment quickly among the few entrants.
The catch: "early promise" in phase 2 or exploratory data does not equal clinical superiority. Direct head-to-head comparison data, phase 3 confirmation, and real-world efficacy will determine which drug becomes standard. Novartis has first-to-market advantage and label breadth; Relay has early efficacy signals. Both matter, but neither is yet conclusive.
What clinicians need to watch
If you treat vascular anomalies, you should request access to Relay's published trial results (when available) and compare them directly to Vijoice's phase 3 data. Early-stage findings often don't survive late-stage testing. Efficacy, tolerability, dosing frequency, and cost will all influence which drug you reach for first. Until phase 3 data exist and are published, treat Relay's early results as promising but not yet definitive.
Track Relay's regulatory timeline; in rare disease, a second effective option can change patient access and standard-of-care debates quickly. Expect announcements on phase 3 initiation or advancement within the next 12 to 18 months.